Michael King, Chief Financial Officer of Miletus Biotechnology, is an accomplished pharmaceutical and biotechnology executive with more than 30 years of experience as a CFO and CBO in corporate finance and management consulting.

Michael is currently CFO of Primera Therapeutics, a pioneer of the gene editing platform developed in the Mayo Clinic labs of Dr. Steven Ekker and Dr. Karl Clark to precisely correct a patient’s mutated mtDNA and discover transformational therapies for mitochondrial disease.

He was CFO of Hibiscus Biotechnology, CBO of Adaptive Phage Therapeutics during its $61 million Series A, and CFO and CBO of PDS Biotechnology (PDSB), serving from 2014 through its reverse merger with Edge Therapeutics in March 2019, then continuing as a senior advisor or CFO until 2021.

Michael was a long-time senior advisor at Akari Therapeutics (AKTX), where he played a key role in the merger and concurrent $75 million PIPE that formed the company in 2015, and then continued to serve until 2022.

Michael was CFO and CBO of Aprecia Pharmaceuticals, where he raised more than $70 million in private financing, and CBO of Atrin Pharmaceuticals (now Aprea Therapeutics, APRE). He was a member of the U.S. Executive Committee for Sandoz GmbH, the $10 billion subsidiary of Novartis AG.

Michael is a former management consultant with McKinsey & Company in its Pharmaceutical and Medical Products practice, based out of the New York office.